Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 708

1.

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Corbin AS, O'Hare T, Gu Z, Kraft IL, Eiring AM, Khorashad JS, Pomicter AD, Zhang TY, Eide CA, Manley PW, Cortes JE, Druker BJ, Deininger MW.

Cancer Res. 2013 Sep 15;73(18):5775-86. doi: 10.1158/0008-5472.CAN-13-1318. Epub 2013 Jul 25.

2.

Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.

Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, Lai D, Jorgensen H, Ringrose A, Wang HM, Lambie K, Nakamoto H, Saw KM, Turhan A, Arlinghaus R, Paul J, Stobo J, Barnett MJ, Eaves A, Eaves CJ, Holyoake TL, Jiang X.

J Natl Cancer Inst. 2013 Mar 20;105(6):405-23. doi: 10.1093/jnci/djt006. Epub 2013 Feb 27.

3.

Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.

Ng KP, Manjeri A, Lee KL, Huang W, Tan SY, Chuah CT, Poellinger L, Ong ST.

Blood. 2014 May 22;123(21):3316-26. doi: 10.1182/blood-2013-07-511907. Epub 2014 Apr 4.

4.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R.

Blood. 2004 Apr 15;103(8):3167-74. Epub 2003 Dec 11.

5.

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ.

J Clin Invest. 2011 Jan;121(1):396-409. doi: 10.1172/JCI35721. Epub 2010 Dec 13. Erratum in: J Clin Invest. 2011 Mar 1;121(3):1222.

6.

[A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].

Song YP, Fang BJ, Wei XD, Zheng S.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Dec;13(6):1004-9. Chinese.

PMID:
16403268
7.

Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.

Reddiconto G, Toto C, Palamà I, De Leo S, de Luca E, De Matteis S, Dini L, Passerini CG, Di Renzo N, Maffia M, Coluccia AM.

Blood. 2012 Mar 8;119(10):2335-45. doi: 10.1182/blood-2011-06-361261. Epub 2012 Jan 18.

8.

Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.

Xu XH, Gan YC, Xu GB, Chen T, Zhou H, Tang JF, Gu Y, Xu F, Xie YY, Zhao XY, Xu RZ.

J Zhejiang Univ Sci B. 2012 Nov;13(11):867-74. doi: 10.1631/jzus.B1200021.

9.

Potential role of Notch signalling in CD34+ chronic myeloid leukaemia cells: cross-talk between Notch and BCR-ABL.

Aljedai A, Buckle AM, Hiwarkar P, Syed F.

PLoS One. 2015 Apr 7;10(4):e0123016. doi: 10.1371/journal.pone.0123016. eCollection 2015.

10.

Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors.

Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, Bhatia R.

Leukemia. 2008 Apr;22(4):748-55. doi: 10.1038/sj.leu.2405086. Epub 2008 Feb 14.

PMID:
18273048
11.

The stem cell factor-c-KIT pathway must be inhibited to enable apoptosis induced by BCR-ABL inhibitors in chronic myelogenous leukemia cells.

Belloc F, Airiau K, Jeanneteau M, Garcia M, Guérin E, Lippert E, Moreau-Gaudry F, Mahon FX.

Leukemia. 2009 Apr;23(4):679-85. doi: 10.1038/leu.2008.364. Epub 2009 Jan 22.

PMID:
19158834
12.

Targeting abnormal DNA double-strand break repair in tyrosine kinase inhibitor-resistant chronic myeloid leukemias.

Tobin LA, Robert C, Rapoport AP, Gojo I, Baer MR, Tomkinson AE, Rassool FV.

Oncogene. 2013 Apr 4;32(14):1784-93. doi: 10.1038/onc.2012.203. Epub 2012 May 28.

13.

Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival.

Hamilton A, Helgason GV, Schemionek M, Zhang B, Myssina S, Allan EK, Nicolini FE, Müller-Tidow C, Bhatia R, Brunton VG, Koschmieder S, Holyoake TL.

Blood. 2012 Feb 9;119(6):1501-10. doi: 10.1182/blood-2010-12-326843. Epub 2011 Dec 19.

14.

Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.

Wu LX, Wu Y, Chen RJ, Liu Y, Huang LS, Lou LG, Zheng ZH, Chen YZ, Xu JH.

Acta Pharmacol Sin. 2014 Mar;35(3):401-9. doi: 10.1038/aps.2013.180. Epub 2014 Feb 3.

15.

HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.

Sugimoto Y, Nakamura S, Okinaka K, Hirano I, Ono T, Shigeno K, Shinjo K, Ohnishi K.

Leuk Res. 2008 Jun;32(6):962-71. doi: 10.1016/j.leukres.2007.11.034. Epub 2008 Jan 10.

PMID:
18190961
16.

Combined STAT3 and BCR-ABL1 inhibition induces synthetic lethality in therapy-resistant chronic myeloid leukemia.

Eiring AM, Page BD, Kraft IL, Mason CC, Vellore NA, Resetca D, Zabriskie MS, Zhang TY, Khorashad JS, Engar AJ, Reynolds KR, Anderson DJ, Senina A, Pomicter AD, Arpin CC, Ahmad S, Heaton WL, Tantravahi SK, Todic A, Colaguori R, Moriggl R, Wilson DJ, Baron R, O'Hare T, Gunning PT, Deininger MW.

Leukemia. 2015 Mar;29(3):586-97. doi: 10.1038/leu.2014.245. Epub 2014 Aug 19.

17.
18.

Differential contributions of STAT5A and STAT5B to stress protection and tyrosine kinase inhibitor resistance of chronic myeloid leukemia stem/progenitor cells.

Casetti L, Martin-Lannerée S, Najjar I, Plo I, Augé S, Roy L, Chomel JC, Lauret E, Turhan AG, Dusanter-Fourt I.

Cancer Res. 2013 Apr 1;73(7):2052-8. doi: 10.1158/0008-5472.CAN-12-3955. Epub 2013 Feb 11.

19.

Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.

Lemoli RM, Salvestrini V, Bianchi E, Bertolini F, Fogli M, Amabile M, Tafuri A, Salati S, Zini R, Testoni N, Rabascio C, Rossi L, Martin-Padura I, Castagnetti F, Marighetti P, Martinelli G, Baccarani M, Ferrari S, Manfredini R.

Blood. 2009 Dec 10;114(25):5191-200. doi: 10.1182/blood-2008-08-176016.

20.

shRNA library screening identifies nucleocytoplasmic transport as a mediator of BCR-ABL1 kinase-independent resistance.

Khorashad JS, Eiring AM, Mason CC, Gantz KC, Bowler AD, Redwine HM, Yu F, Kraft IL, Pomicter AD, Reynolds KR, Iovino AJ, Zabriskie MS, Heaton WL, Tantravahi SK, Kauffman M, Shacham S, Chenchik A, Bonneau K, Ullman KS, O'Hare T, Deininger MW.

Blood. 2015 Mar 12;125(11):1772-81. doi: 10.1182/blood-2014-08-588855. Epub 2015 Jan 8.

Supplemental Content

Support Center